Drug intelligence / Profile preview

zifexaban

Development stage: Unknown
Lead developer: Tianjin Institute of Pharmaceutical Research
Modality: Small Molecules
Administration: Oral

Overview

Zifexaban (Chinese name: 知非沙班) is a small molecule oral anticoagulant developed by Tianjin Institute of Pharmaceutical Research. It is classified as a novel chemical drug (Class 1 in China). Zifexaban acts as a direct inhibitor of coagulation Factor Xa, thereby interrupting the blood coagulation cascade and preventing thrombus formation. Its primary indication under clinical investigation is the treatment of venous thrombosis. As of now, it has reached Phase 2 clinical trials in China[1].

Other names: 知非沙班

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on zifexaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zifexaban.

Explore the full profile